Blackstone Inc
NGM

Blackstone Inc’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Blackstone Inc’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-104,432
Closed -$1.34M – 249
2022
Q2 		$1.34M Buy
+104,432
New +$1.45M ﹤0.01% 135
2021
Q4 		– Sell
-188,752
Closed -$3.97M – 617
2021
Q3 		$3.97M Buy
+188,752
New +$4.16M 0.01% 275
2019
Q3 		– Sell
-10,000
Closed -$146K – 101
2019
Q2 		$146K Buy
+10,000
New +$146K ﹤0.01% 88

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Blackstone Inc's NGM Position: Q3 2022 in Review

Blackstone Inc sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2022, closing a stake of 104,432 shares — an estimated $1.34M sold.

Blackstone Inc first reported a position in NGM in Q2 2019 and held it in 3 quarters. The position peaked at $3.97M in Q3 2021. 128 funds tracked by Wall St. Rank hold NGM as of Q3 2022.

  • Blackstone Inc reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Blackstone Inc sold 104,432 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $1.34M.
  • Blackstone Inc first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Blackstone Inc's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $3.97M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Blackstone Inc's 13F filing for Q3 2022, filed 14 Nov 2022.